Epcoritamab

艾可瑞妥单抗

Report date: 2026/05/18 20:02:07

Base Information

Drug NameEpcoritamab
Drug Alias NameDuobody-CD3-CD20DuoBody-CD3xCD20Epcoritamab-byspAnti-CD3 anti-CD20 bispecific antibody(Genmab/AbbVie)EPKINLY +[10] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Bispecific monoclonal antibodyBiologics > T cell engagers
Mechanisms of ActionAnti-CD20Anti-CD3Antibody-dependent cell-mediated cytotoxicity (ADCC) effects +[4] 
TargetsB-lymphocyte antigen CD20T cell surface glycoprotein CD3
Therapy Area/IndicationsPrimary mediastinal B cell lymphomaRichter's SyndromeLymphoproliferative Disorders +[12] 
Global Approved IndicationsPrimary mediastinal B cell lymphomaLymphoma, FollicularLymphoma, Large B-Cell, Diffuse
Approved Indications in ChinaLymphoma, Follicular
Original Approved Country/TerritoryUnited States
Original Approved Date2023/05/19
Country/TerritoryCzechiaBelgiumBulgaria +[38] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGenmab A/SAbbvie Inc
China Registration ClassN/A

Develop Information

Active CompaniesGenmab KKGenmab Us IncGenmab A/S +[10] 
Inactive CompaniesN/A
Active IndicationsPrimary mediastinal B cell lymphomaRichter's SyndromeLymphoproliferative Disorders +[11] 
Inactive IndicationsLymphoma, Mantle-Cell

Other Information

ATC CodeN/A
Related LinksWikipediaDrugBankKEGG